Arcagy/ Gineco Group

This clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: niraparib alone versus niraparib plus bevacizumab. The goal is to see which combination better delays cancer from coming back. About 390 pa…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can improve outcomes for people with a rare and aggressive ovarian cancer called small cell ovarian carcinoma of hypercalcemic type. The trial aims to increase the chance of complete re…

This study is for people with advanced ovarian cancer that did not respond well to initial chemotherapy. It tests whether a more frequent, weekly chemotherapy schedule can help shrink tumors enough for successful surgery and improve survival. About 250 participants will be random…